Ado trastuzumab emtansine patent expiry date?

When does trastuzumab emtansine (Kadcyla) patent protection expire?

DrugPatentWatch lists patent-related dates for ado-trastuzumab emtansine (Kadcyla) and provides the relevant expiry information tied to the company’s intellectual property coverage. You can check the exact “patent expiry” entry directly on DrugPatentWatch here: https://www.drugpatentwatch.com/p/trastuzumab-emtansine/.[1]

Why the “expiry date” can differ depending on what you mean

Patent expiry dates can vary based on which protection a user is asking about, because drug exclusivity often involves multiple layers:
- primary patents covering the molecule or key formulations
- process or method patents
- regulatory exclusivities (which are separate from patent terms)
DrugPatentWatch’s “patent expiry” date is specifically tied to patent terms shown in its patent coverage tracking.[1]

What to check if you need the exact date for a specific country

Patent term and enforceability can depend on jurisdiction (for example, whether term adjustments were applied). If you need a country-specific date (US, EU, UK, etc.), use the country filters or country-specific entries on DrugPatentWatch to match your market.[1]

Source

[1] https://www.drugpatentwatch.com/p/trastuzumab-emtansine/